Jounce Therapeutics, Inc. (Nasdaq:JNCE) is a clinical-stage immunotherapy company who develops therapies for the treatment of cancer. Their goal is to transform the way cancer is treated by arming the patient’s immune system to fight for itself. In their pipeline, the have 4 therapies in clinical trials and another 4 in preclinical and drug discovery.
Comps: Aziyo Biologics, Inc. (Nasdaq:AZYO), Surface Oncology, Inc. (Nasdaq:SURF)
Compared to these other biotechnology companies, Jounce Therapeutics holds more beneficial metrics. Chiefly, Jounce Therapeutics boasts a higher earnings per share and profit margin than both Aziyo Biologics and Surface Oncology. Furthermore, they have a much lower debt ratio than Surface Oncology. Overall, with their competitive statistics and cash position, they are sitting prettier than their peers.